🔎 Trials Near Me

Akèy › Leksemi mieloïd egi › Utah › Salt Lake City

Etid klinik pou Leksemi mieloïd egi nan Salt Lake City, UT

17 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Salt Lake City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Ap rekriteFaz 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
  • George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT05564390

Ivosidenib as Post-HSCT Maintenance for AML

Ap rekriteFaz 2
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Laj 18 a 75 · Tout sèks · Mizajou Oct 5, 2026 · NCT06707493

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Laj 18 a 59 · Tout sèks · Mizajou Sep 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Ap rekriteFaz 3
  • Intermountain Healthcare LDS Hospital, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06852222

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
  • George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Ap rekriteFaz 3
  • Primary Children's Hospital, Salt Lake City
6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Ap rekriteFaz 2
  • Huntsman Cancer Institute, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Ap rekriteFaz 2
  • Huntsman Cancer Institute - University of Utah Health, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Ap rekriteFaz 3
  • Primary Children's Hospital, Salt Lake City
29 Days – 21 Years · Tout sèks · Mizajou Aug 24, 2026 · NCT05183035

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Ap rekriteEtid obsèvasyon
  • University of Utah, Salt Lake City
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Ap rekriteFaz 1
  • University of Utah, Salt Lake City
Laj 13 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT04771572

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Ap rekriteFaz 1
  • University of Utah, Salt Lake City
Jiska laj 21 · Tout sèks · Mizajou Apr 22, 2026 · NCT05101551

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Ap rekriteFaz 1/2
  • Huntsman Cancer Institute, Salt Lake City
  • Intermountain Healthcare, Salt Lake City
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555

Etid Leksemi mieloïd egi nan lòt vil

Lòt etid nan Salt Lake City

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.